The authors confirm that all data underlying the findings are fully available without restriction. General synthetic and analytical methods are detailed in [Text S1](#pone.0111782.s041){ref-type="supplementary-material"}. Raw NMR data for all compounds are available from The University of Sydney eScholarship Repository \[<http://hdl.handle.net/2123/10506>\]. The open electronic laboratory notebook for experiments carried out April--August 2013 is available from The University of Sydney eScholarship Repository \[<http://hdl.handle.net/2123/10461>\]; all other experiments are summarised in [Spreadsheet S1](#pone.0111782.s042){ref-type="supplementary-material"}.

Introduction {#s1}
============

Infection by *M. tuberculosis* resulting in symptomatic tuberculosis (TB) can be fatal without treatment. In 2012, TB was responsible for the deaths of 1.3 million people and a further 8.6 million people were infected [@pone.0111782-World1]. Globally, an estimated two billion people carry latent TB and are susceptible to developing active TB. Current first-line treatments include the "short-course-chemotherapy" regime, which involves combinations of rifampicin, isoniazid, pyrazinamide and ethambutol, taken over at least 6 months [@pone.0111782-Zumia1]. These drugs have been in use since the 1960s; the recent FDA approval of bedaquiline [@pone.0111782-Interim1] makes this drug the first new treatment for TB to be approved in 40 years. The spread of partially- and totally drug resistant strains makes the development of new treatments (preferably targeting new cellular mechanisms) a priority [@pone.0111782-World1].

GlaxoSmithKline (GSK) recently published the structures and anti-TB activities of 177 small molecules as part of a deposition of open data [@pone.0111782-Ballell1]. These leads were identified out of a pool of ∼20000 molecules, chosen from the GSK corporate compound collection based on favourable cell permeability and drug-like parameters. Of the 177 leads, seven compounds contained a thiophene spirocycle core; these were termed Spiros by GSK, represented by GSK2200150A ([Figure 1](#pone-0111782-g001){ref-type="fig"}).

![The GSK HTS campaign identified GSK2200150A, which is representative of the GSK Spiros family of anti-TB leads (A). (B) The optimised Spiros analogue developed by GSK [@pone.0111782-Remuin1]. (C) Existing anti-tubercular candidates that have a mode of action that involves MmpL3.](pone.0111782.g001){#pone-0111782-g001}

The members of the Spiros series are excellent starting points for the development of new anti-TB agents. The compounds were identified following a number of screens that evaluated their inhibition of the growth of mycobacteria, cytotoxicity and physical properties. The Spiros appear to affect an essential membrane transport protein (MmpL3) of *M. tuberculosis* [@pone.0111782-Remuin1]. There are no currently-approved drugs that target MmpL3, but four structurally dissimilar compounds (C, [Figure 1](#pone-0111782-g001){ref-type="fig"}) have been identified as acting on MmpL3 [@pone.0111782-Tahlan1]--[@pone.0111782-LaRosa1] as well as a more recent set of indoleamides [@pone.0111782-Lun1]. In 2012 SQ109 completed a phase IIa clinical trial for pulmonary TB [@pone.0111782-Clinical1]. The Spiros analogues are not overtly similar in structure to these compounds; further investigation into the specific mode of action at MmpL3 is clearly required, but it is a desirable property of any new antitubercular compound that it should have a target different to existing therapeutics.

Screening campaigns frequently use commercial libraries that understandably lack synthetic provenance. The synthesis of the secondary amine spirocycle core has been incompletely reported in the patent literature and a synthesis of the GSK hit compound (GSK2200150A) was described in the academic literature but with incomplete data and limited information on analog synthesis. [@pone.0111782-Ballell1]--[@pone.0111782-Remuin1], [@pone.0111782-Shao1]. We rationalised that Spiros analogues could be rapidly produced by first constructing the core using an oxa-Pictet--Spengler reaction followed by final stage diversification from the secondary amine **3** ([Figure 2](#pone-0111782-g002){ref-type="fig"}). This would allow the rapid synthesis of new Spiros analogues in three steps and the faster progression of this series in a hit-to-lead campaign.

![Potential for the rapid synthesis of Spiros analogues via a common 2° amine intermediate 3.\
(A) An existing oxa-Pictet--Spengler reaction can be used to form the spirocycle core (blue) as the 2° amine **3** [@pone.0111782-Shao1]. (B) Strategy to diversify from the 2° core **3** to produce Spiros analogues (C) with variation at the piperidine nitrogen (red).](pone.0111782.g002){#pone-0111782-g002}

We herein describe this work which was conducted using an electronic laboratory notebook on the internet [@pone.0111782-Robertson1] and an open source research philosophy that had shown efficiency gains in the discovery of a synthetic route to a drug used in the treatment of schistosomiasis [@pone.0111782-Woelfle1]. The licence governing such work is that the research may be used for any purpose, including for financial gain, provided the project is cited. The relevant laboratory notebook, containing a browseable snapshot of the experiments and all the data for the period April--August 2013, has been deposited online [@pone.0111782-Badiola1]. Data for remaining experiments (period late August--December 2013) are included in [Spreadsheet S1](#pone.0111782.s042){ref-type="supplementary-material"} rather than the electronic laboratory notebook due to a local technical difficulty at the time these data were collected.

Results and Discussion {#s2}
======================

Synthesis of the Spiros Analogues {#s2a}
---------------------------------

Our first synthetic approach was the use of compound **5** to make **3** with an oxa-Pictet Spengler reaction ([Figure 3](#pone-0111782-g003){ref-type="fig"}). We adapted the patent procedure (A, [Figure 2](#pone-0111782-g002){ref-type="fig"}) [@pone.0111782-Shao1] by using 4-piperidone **5**, instead of the corresponding ketal **2**, since substitution of the ketal for the ketone in the oxa-Pictet--Spengler reaction should have a limited effect the reaction outcome [@pone.0111782-Bouguerne1]. The ketone is commercially available but was easily prepared from commercial 4-benzylpiperidinone **4** (A, [Figure 3](#pone-0111782-g003){ref-type="fig"}) [@pone.0111782-Ram1] a compound that was itself later used. However, the harsh conditions of the cyclization (excess triflic acid) resulted in the formation of intractable mixtures.

![Synthesis of the core 70 was attempted using conditions adapted from the literature [@pone.0111782-Shao1].\
(A) *N* -Debenzylation of **4** was achieved under palladium-catalysed transfer hydrogenation conditions [@pone.0111782-Ram1]. (B) Reaction of the ketone **5** with thiopheneethanol **1** in the presence of strong Brønsted acids did not produce the expected spirocycle **3**.](pone.0111782.g003){#pone-0111782-g003}

Several reaction variables were explored to promote cyclisation, such as reducing the amount of acid, using the less acidic methanesulfonic acid [@pone.0111782-McCallum1]--[@pone.0111782-Bordwell1], introducing a non-polar solvent (toluene or dioxane) and heating the reaction. These efforts resulted in either partial recovery of the thiophene starting material along with a complex product mixture or decomposition and the formation of polar compounds that were not identified.

The ketal **2** may therefore be crucial in this transformation where precise tuning of reactivity and conditions is necessary to promote conversion but not decomposition. However, formation of this ketal would unfavourably introduce another step in the synthesis (A, red, [Figure 4](#pone-0111782-g004){ref-type="fig"}). We therefore devised an alternate strategy for accessing the secondary amine **3**: carrying out the oxa-Pictet--Spengler reaction using **4** prior to removal of the *N*-benzyl group (B).

![Re-evaluating the route to the 2° amine core 3 (blue).\
(A) The attempted route based on the patent literature procedure [@pone.0111782-Shao1]. The dotted lines represent the additional step (red) required to attempt cyclisation strictly under the patent conditions. (B) The revised strategy: cyclise to give **6** followed by debenzylation to give the 2° amine **3** (blue).](pone.0111782.g004){#pone-0111782-g004}

The first step of the revised strategy proved effective; the *N*-benzylated core (**6**) was obtained in consistently good yield over a number of repeats (A, [Figure 5](#pone-0111782-g005){ref-type="fig"}). The reaction was promoted by 1.5 equivalents of methanesulfonic acid instead of triflic acid, the former being easier to handle. To counter the reduced acidity, the reaction temperature was increased. Lowering the acid loading or reaction time gave a mixture of the product **6** and starting material; the ketone **4** was inseparable from the product **6** in the post-reaction workup or by flash chromatography. The methanesulfonic acid-mediated reaction initially carried out was the most effective at cleanly obtaining the desired spirocycle **6**.

![Executing the revised strategy towards the synthesis of spirocycle core as the 2° amine 3.\
(A) The acid-mediated cyclisation. (B) Attempts to synthesise the 2° amine using catalytic hydrogenolysis. (C) 1-chloroethyl chloroformate was effective at producing the secondary amine **3**. (D) 2-chloroethyl chloroformate resulted in incomplete deprotection of **6**.](pone.0111782.g005){#pone-0111782-g005}

The next step was the removal of the *N*-benzyl group from **6** to give the secondary amine **3** (B to D, [Figure 5](#pone-0111782-g005){ref-type="fig"}). The *N*-benzylated spirocycle **6** was stable to a variety of common palladium-catalysed hydrogenolysis conditions (B). The transfer hydrogenation conditions used in the preparation of 4-piperidinone **5** were ineffective; starting material **6** was recovered. Subsequent attempts were made using different combinations of pressure (hydrogen gas up to 8.3 bar), transfer hydrogenation and extended reaction times. In all attempts, starting material was recovered with minimal loss of material.

We turned instead to debenzylation conditions mediated by 1-chloroethyl chloroformate **7** (green), which gave the expected secondary amine **3** (blue) in excellent yield (C, [Figure 5](#pone-0111782-g005){ref-type="fig"}). The debenzylation proceeds presumably *via* a carbamate intermediate following the reaction of the starting material **6** with the chloroformate **7** and loss of benzyl chloride [@pone.0111782-Olofson1]--[@pone.0111782-Olofson2]. Subsequent decarboxylation, promoted by the excess of methanol and reflux conditions, produced the desired secondary amine **3** [@pone.0111782-Olofson1]--[@pone.0111782-Olofson2]. Isolation of the carbamate **9** when 2-chloroethyl chloroformate **8** was used is consistent with the proposed mechanism (D); the initial *N*-debenzylation step would be unaffected given the similar reactivity of the chloroformate functional groups, but methanol attack on the secondary carbon to lose the β-chloride would be less likely than attack on the tertiary carbon to lose the α-chloride. The secondary amine **3** was obtained, ready for final stage diversification in ∼84% yield over two steps.

Diversification from the secondary amine **3** using reductive amination and acylating conditions enabled the rapid synthesis of a variety of compounds in moderate to good yield ([Figure 6](#pone-0111782-g006){ref-type="fig"}). The sodium triacetoxyborohydride-mediated reductive amination procedure was adapted from the literature [@pone.0111782-Oberdorf1]--[@pone.0111782-AbdelMagid1]. Acylation of the amine **3** was achieved using aroyl chlorides. All candidate compounds were designed to exhibit acceptable calculated logP values.

![Diversification in the final step.\
The conditions for reductive amination (A) and acylation (B) of 3 to produce the final Spiros analogs **10--18** the yields reported are of pure material isolated following flash chromatography on silica.](pone.0111782.g006){#pone-0111782-g006}

The acylation products **16** to **18** and the arylpyrrole **14** exhibited convoluted NMR spectra. The ^13^C{^1^H}-NMR spectra of **16** to **18** contained the signals expected from the carbon atoms in the carbonyl groups (165 to 175 ppm in CDCl~3~) indicating formation of the amide bond, but ^1^H--^13^C{^1^H} Heteronuclear Single Quantum Correlation (HSQC) spectroscopy was required to elucidate the piperidine ^13^C{^1^H} region (A, [Figure 7](#pone-0111782-g007){ref-type="fig"}); the broad ^1^H signals correlated to the aliphatic region of the ^13^C{^1^H} spectrum (B) were consistent with the piperidine ring protons and all environments were accounted for. The broad signals observed for the methylene protons on the oxygen-containing ring in the compounds containing an exocyclic amide bond (i.e. compounds **16--18**) most likely arise from the chirality exhibited by the individual rotamers (C and D), which, though in dynamic equilibrium *via* an achiral intermediate (B), make the protons attached to these carbons diastereotopic. Additional experiments were carried out on the acylated product **16**, which showed temperature and magnetic field dependence (E) consistent with rapid rotation of the amide bond; at higher fields or lower temperatures peaks for the individual rotamers, and their more convoluted splitting patterns, became clear.

![The piperidine nitrogen signals of the acylated products can be visualised by HSQC experiments.\
The ^1^H-NMR and ^13^C{^1^H}-NMR spectra respectively displayed on the x- and y-axes of the HSQC spectra are projections of the corresponding one-dimensional NMR experiments and are displayed for clarity. (A) The aliphatic region of the ^1^H--^13^C{^1^H} HSQC spectrum of **16**; the red arrows indicate the ^1^H signals corresponding to the piperidine protons (attached to the red ring of the structure). The corresponding piperidine carbon signals on the y-axis (circled red) are unclear in the ^13^C{^1^H} spectrum. (B) Rotation around the amide bond generates chiral rotamers (C and D) dictated by the π-system of the benzamide, which makes the methylene protons in the oxygen-containing ring diastereotopic, (E) Variable magnetic field temperature and NMR experiments showing coalescence of methylene signals for compound **16**. At lower temperature the diastereotopic oxygen-containing ring protons (E) exhibited higher order coupling, arising from the individual rotamers ([Figure S39](#pone.0111782.s039){ref-type="supplementary-material"}) and the ^13^C{^1^H} NMR spectrum exhibited complete resolution of the piperidine ring carbon signals ([Figure S40](#pone.0111782.s040){ref-type="supplementary-material"}). Raw data may be found in [Dataset S1](#pone.0111782.s043){ref-type="supplementary-material"}.](pone.0111782.g007){#pone-0111782-g007}

Activity of the Spiros Analogues {#s2b}
--------------------------------

The activities of the compounds containing the spirocycle core (**3, 6, 9--18**) were determined against the virulent *M.tuberculosis* strain (H37Rv) ([Table 1](#pone-0111782-t001){ref-type="table"}). Initially, *M. tuberculosis* H37Rv was exposed to a single compound dose of 100 µM for 7 days, and survival was determined in comparison to vehicle-treated bacterial cells using a Resazurin microtiter assay of growth inhibition [@pone.0111782-Magnet1]. The potency of compounds displaying activity at 100 µM was determined by calculating the concentration of drug inhibiting 50% of bacterial growth (IC~50~). Excellent inhibitory activity against H37Rv for compounds containing the *N*-benzyl/pyrrole-type centres (**6**, **10**, **11**, **13** and **14**) was observed other than for **12**; the cyclohexyl-containing spirocycle **1**, the secondary amine **3** and the *N*-acyl-type spirocycles (**9, 16--18**) were inactive. The presence of the *N*-CH~2~-Ar group appeared to be a necessary but not sufficient condition for significant activity against H37Rv, but amide-type functionality was detrimental to the potency of the molecules. Novel compounds **13** and **14** were the most potent with activity comparable to the Spiros anti-TB compounds identified and developed by GSK [@pone.0111782-Ballell1]--[@pone.0111782-Remuin1].

10.1371/journal.pone.0111782.t001

###### Anti-tubercular activity of the synthesised Spiros analogues.

![](pone.0111782.t001){#pone-0111782-t001-1}

  Entry    Compound                  CLogP                   H37Rv IC~50~ (µM)   THP IC~5~ (µM)
  ------- ---------- -------------------------------------- ------------------- ----------------
  1         **3**                     0.83                         \>100              n/a
  2         **6**                     3.1                            5                200
  3         **9**                     2.1                          \>100              n/a
  4         **10**                    3.0                          1.25               100
  5         **11**                    3.0                           10               \>200
  6         **12**                    2.2                          \>100              n/a
  7         **13**                    3.8                          1.25                50
  8         **14**    5.4[\*](#nt102){ref-type="table-fn"}         1.25               6.3
  9         **15**                    3.2                          \>100              n/a
  10        **16**                    1.7                          \>100              n/a
  11        **17**                    2.6                          \>100              n/a
  12        **18**                    2.6                          \>100              n/a

Compounds with a minimum inhibitory concentration \>25000 nM were not tested in the inhibition assay of starting concentration 2 mM. The CLogP were calculated using ChemBioDraw Ultra 12.0.3 and the values are a guide only. CLogP values of rifampicin were also calculated using the same method for consistency.

**\*The CLogP value was calculated for the free compound.**

Toxicity of compounds displaying anti-H37Rv activity was assessed using the human monocytic cell line THP1 ([Table 1](#pone-0111782-t001){ref-type="table"}). The IC~50~ against THP was calculated and was compared to the IC~50~ calculated against *M. tuberculosis* H37Rv. Compounds **6**, **10**, **11** and **13** displayed THP1 toxicity at relatively high concentrations (\>50 µM), suggesting potential for the future development of these compounds. Compounds **6** and **11** were less toxic than the original GSK structure (**10**) yet were also less potent against H37Rv. Compound **14** was highly active against H37Rv however was toxic against THP1 in the low µM range.

Conclusion {#s3}
==========

A three-step synthesis of new TB drug leads is reported that will provide rapid access to potent compounds that may be used in a future assessment of this series. This should both aid in the synthesis of existing analogues for examination of their pharmacokinetic properties and the synthesis of diverse new analogues in this series to optimise potency and drug likeness as well as to further mechanism of action studies. Future participants in such efforts are encouraged to adopt the open platform that has already been developed for full data sharing and collaboration.

Materials and Methods {#s4}
=====================

General Chemistry {#s4a}
-----------------

General synthetic and analytical methods are detailed in [Text S1](#pone.0111782.s041){ref-type="supplementary-material"}. Raw NMR data for all compounds are available from The University of Sydney eScholarship Repository [@pone.0111782-Badiola2]. The open electronic laboratory notebook for experiments carried out April--August 2013 is available from The University of Sydney eScholarship Repository [@pone.0111782-Badiola1]; all other experiments are summarised in [Spreadsheet S1](#pone.0111782.s042){ref-type="supplementary-material"}.

6′,7′-Dihydrospiro\[piperidine-4,4′-thieno\[3,2-*c*\]pyran\] 3 {#s4b}
--------------------------------------------------------------

This compound exists in the literature but no data are reported [@pone.0111782-Oberdorf1]. To a stirred solution of **6** (2.3 g, 7.7 mmol, 1 equiv.) in anhydrous THF (200 mL) under argon at −78°C was added 1-chloroethyl chloroformate (1.6 mL, 15 mmol, 2 equiv.). The reaction mixture was stirred for 30 min then allowed to warm to rt. THF was removed under reduced pressure leaving a residual volume of ∼10 mL which was diluted with methanol (200 mL) and heated at reflux for 20 min. The now clear brown solution was concentrated under reduced pressure to give the crude product as a brown foam (2.8 g). The crude material was purified by flash chromatography on silica (5∶100∶0.5, CH~3~OH∶CH~2~Cl~2~∶NH~4~OH, v/v to 10∶100∶1, CH~3~OH∶CH~2~Cl~2~∶NH~4~OH, v/v) to give *the title compound* as a pale brown solid (1.6 g, 99%); mp 86--88°C; ν~max~ (film)/cm^−1^ 2953, 2923, 1072, 1050, 741, 654; δ~H~ (500 MHz; CDCl~3~) 7.06 (d, *J* = 5.2 Hz, 1 *H*), 6.79 (d, *J* = 5.2 Hz, 1 *H*), 3.93 (t~app~, *J* = 5.4 Hz, 2 *H*), 3.06--3.01 (m, 2 *H*), 2.90--2.87 (m, 2 *H*), 2.82 (t~app~, *J = *5.3 Hz, 2 *H*), 1.85--1.78 (m, 4 *H*), 1.66 (brs, 1 *H*) ([Figure S1](#pone.0111782.s001){ref-type="supplementary-material"}); δ~C~ (126 MHz; CDCl~3~) 141.6, 132.5, 124.5, 122.4, 73.9, 59.1, 42.2, 37.0, 26.0 ([Figure S2](#pone.0111782.s002){ref-type="supplementary-material"}); **^1^**H --^13^C HSQC ([Figure S3](#pone.0111782.s003){ref-type="supplementary-material"}) and ^1^H --^13^C{^1^H} HMBC ([Figure S4](#pone.0111782.s004){ref-type="supplementary-material"}) spectra also supplied; Anal. Calcd. for C~11~H~15~NOS: C, 63.12; H, 7.22; N, 6.69. Found: C, 63.46; H, 7.56; N, 6.61.

1-Benzyl-6′,7′-dihydrospiro\[piperidine-4,4′-thieno\[3,2-*c*\]pyran\] 6 {#s4c}
-----------------------------------------------------------------------

To a vigorously stirred solution of thiopheneethanol (0.50 mL, 4.5 mmol, 1 equiv.) and 1-benzyl-4-piperidinone (0.80 mL, 4.5 mmol, 1 equiv.) in toluene (50 mL) was added methanesulfonic acid (0.29 mL, 4.5 mmol, 1 equiv.). The reaction mixture was heated at reflux (oil bath at 130°C) for 16 h and allowed to cool to rt. The mixture was diluted with ethyl acetate (50 mL) and washed with saturated NaHCO~3~ (30 mL). The aqueous fraction was extracted with ethyl acetate (2×30 mL), further basified with solid sodium hydroxide (4.0 g) and extracted with ethyl acetate (2×30 mL). The combined organic fractions were dried (Na~2~SO~4~) and concentrated under reduced pressure to give the crude product as a dark brown oil (1.7 g). The crude material was purified by flash chromatography on silica (10--50% ethyl acetate/hexanes) to give *the title compound* as a pale yellow oil (1.2 g, 86%); ν~max~ (film)/cm^−1^ 2936, 2813, 1075, 854, 672; δ~H~ (500 MHz; CDCl~3~) 7.37--7.31 (m, 4 *H*), 7.27--7.24 (m, 1 *H*), 7.06 (d, *J* = 5.2 Hz, 1 *H*), 6.82 (d, *J* = 5.2 Hz, 1 *H*), 3.93 (t~app~, *J = *5.4 Hz, 2 *H*), 3.56 (s, 2 *H*), 2.82 (t~app~, *J = *5.4 Hz, 2 *H*), 2.74--2.71 (m, 2 *H*), 2.43--2.38 (m, 2 *H*), 2.01--1.95 (m, 2 *H*), 1.86--1.82 (m, 2 *H*) ([Figure S5](#pone.0111782.s005){ref-type="supplementary-material"}); δ~C~ (126 MHz; CDCl~3~) 141.3, 138.6, 132.7, 129.4, 128.3, 127.1, 124.5, 122.3, 73.3, 63.5, 59.1, 49.2, 36.2, 26.0 ([Figure S6](#pone.0111782.s006){ref-type="supplementary-material"}); **^1^**H --^13^C HSQC ([Figure S7](#pone.0111782.s007){ref-type="supplementary-material"}) and ^1^H --^13^C{^1^H} HMBC ([Figure S8](#pone.0111782.s008){ref-type="supplementary-material"}) spectra also supplied; HRMS (ESI) 300.14161 (\[M+H\]^+^), calcd. for C~18~H~22~NOS^+^ 300.14166.

Reductive amination: general procedure 1 {#s4d}
----------------------------------------

This procedure was adapted from the literature [@pone.0111782-Olofson1] [@pone.0111782-Oberdorf1]. Compounds **10--15** were prepared using this method. To a stirred solution of secondary amine **3** (1 equiv.) and the appropriate aldehyde or ketone (1.1 equiv.) in anhydrous dichloromethane (to 50 mM of 70) was added sodium triacetoxyborohydride (1.5 equiv.). The mixture was stirred at rt under argon for 18--24 h then quenched by pouring over saturated NaHCO~3~ solution. The aqueous phase was extracted with dichloromethane (2 times). The combined organic fractions were dried (Na~2~SO~4~) and concentrated under reduced pressure. The crude product was purified by flash chromatography on silica to give the corresponding tertiary amine product.

Acylation: general procedure 2 {#s4e}
------------------------------

Compounds **16--18** were prepared using this method. A stirred solution of secondary amine **3** (1 equiv.) and triethylamine (2 equiv.) in anhydrous dichloromethane (to 0.2 M of 70) under argon was cooled in a brine ice bath. The appropriate acid chloride (1 equiv.)---either benzoyl chloride, 2-bromobenzoyl chloride or 4-bromobenzoyl chloride---was slowly added. The mixture was stirred at temperature for 15 min, slowly allowed to warm to rt and stirred for a further for 12--15 h. The reaction was quenched by pouring over saturated NaHCO~3~ solution. The aqueous phase was extracted with dichloromethane (3 times). The combined organic fractions were dried (Na~2~SO~4~) and concentrated under reduced pressure. The crude product was purified by flash chromatography on silica to give the corresponding amide product.

2-Chloroethyl 6′,7′-dihydrospiro\[piperidine-4,4′-thieno\[3,2-*c*\]pyran\]-1- carboxylate 9 {#s4f}
-------------------------------------------------------------------------------------------

This procedure was adapted from the literature [@pone.0111782-Oberdorf1]. To a stirred solution of **3** (0.40 g, 1.4 mmol, 1 equiv.) in anhydrous THF (35 mL) under argon at −78°C was added 2-chloroethyl chloroformate (0.18 mL, 1.7 mmol, 1.3 equiv.). The reaction mixture was stirred at −78°C for 30 min then allowed to warm to rt. The solvent was removed under reduced pressure and the brownish residue was suspended in methanol (40 mL) and heated at reflux for 1 h. The now clear brown solution was concentrated under reduced pressure to give the crude product as a yellow oil (∼0.5 g). The crude material was purified by flash chromatography on silica (10% ethyl acetate/CH~2~Cl~2~) to *give the title compound* as a colourless oil that solidified when taken to 4°C (0.35 g, 82%); mp 57--60°C; ν~max~ (film)/cm^−1^ 2953, 2923, 1072, 1050, 741, 654; δ~H~ (500 MHz; CDCl~3~) 7.08 (d, *J = *5.2 Hz, 1 *H*), 6.72 (d, *J = *5.2 Hz, 1 *H*), 4.36 (t~app~, *J = *5.7 Hz, 2 *H*), 4.04 (brs, 2 *H*), 3.94 (t~app~, *J = *5.4 Hz, 2 *H*), 3.71 (t, *J = *5.6 Hz, 1 *H*), 3.21 (s, 1 *H*), 2.83 (t, *J = *5.4 Hz, 1 *H*), 1.84--1.81 (m, 1 *H*) ([Figure S9](#pone.0111782.s009){ref-type="supplementary-material"}); δ~C~ (126 MHz; CDCl~3~) 154.9, 140.3, 132.9, 124.1, 122.7, 73.2, 65.0, 59.4, 42.5, 39.9, 25.9 ([Figure S10](#pone.0111782.s010){ref-type="supplementary-material"}); HRMS (ESI) 280.10010 (\[M−Cl\]^+^) calcd. for C~14~H~18~NO~3~S^+^ 280.10019; **^1^**H --^13^C HSQC ([Figure S11](#pone.0111782.s011){ref-type="supplementary-material"}) and ^1^H --^13^C{^1^H} HMBC ([Figure S12](#pone.0111782.s012){ref-type="supplementary-material"}) spectra also supplied; HRMS (ESI) 338.05867 (\[M+Na\]^+^), calcd. for C~14~H~18~ClNO~3~SNa^+^ 338.05881; Anal. Calcd. for C~14~H~18~ClNO~3~S: C, 53.24; H, 5.74; N, 4.44. Found: C, 53.21; H, 5.77; N, 4.40. ^13^C{^1^H}-NMR signals are missing or obscured due to rotamers around the carbamate.

1-((2,3-Dihydrobenzo\[*b*\][@pone.0111782-World1], [@pone.0111782-Ballell1]dioxin-6-yl)methyl)-6′,7′-dihydrospiro\[piperidine- 4,4′-thieno\[3,2-*c*\]pyran\] 10 {#s4g}
---------------------------------------------------------------------------------------------------------------------------------------------------------------

Prepared according to general procedure 1. Following purification by flash chromatography (1∶100∶0.1, CH~3~OH∶CHCl~3~∶NH~4~OH), *the title compound* was obtained as a colourless oil that solidified to a colourless solid when taken to -20°C (52 mg, 58%); mp 106--109°C; ν~max~ (film)/cm^−1^ 2926, 2813, 1505, 1068, 886, 648; δ~H~ (500 MHz; CDCl~3~) 7.06 (d, *J = *5.1 Hz, 1 *H*), 6.88 (s~app~, 1 *H*), 6.84--6.79 (m, 3 *H*), 4.25 (s, 4 *H*), 3.92 (t~app~, *J = *5.3 Hz, 2 *H*), 3.45 (s, 2 *H*), 2.82 (t~app~, *J = *5.3 Hz, 2 *H*), 2.71 (brd~app~, *J = *11.2 Hz, 2 *H*), 2.37 (t~app~, *J = *11.9 Hz, 2 *H*), 1.97 (td~app~, *J = *13.2, 4.0 Hz, 2 *H*), 1.84 (d, *J = *13.0 Hz, 2 *H*) ([Figure S13](#pone.0111782.s013){ref-type="supplementary-material"}); δ~C~ (126 MHz; CDCl~3~) 143.4, 142.7, 141.4, 132.7, 132.0, 124.6, 122.40, 122.30, 118.1, 117.0, 73.4, 64.51, 64.49, 62.9, 59.1, 49.1, 36.3, 26.0 ([Figure S14](#pone.0111782.s014){ref-type="supplementary-material"}); **^1^**H --^13^C HSQC ([Figure S15](#pone.0111782.s015){ref-type="supplementary-material"}) and ^1^H --^13^C{^1^H} HMBC ([Figure S16](#pone.0111782.s016){ref-type="supplementary-material"}) spectra also supplied; HRMS (ESI) 358.14712 (\[M+H\]^+^), calcd. for C~20~H~24~NO~3~S^+^ 358.14714; Anal. Calcd. for C~20~H~23~NO~3~S: C, 67.20; H, 6.49; N, 3.92. Found: C, 66.55; H, 6.54; N, 3.88. Discrepancy in CHN analysis noted, but data consistent with 4M+ H~2~O, i.e. calcd. for C~80~H~94~N~4~O~13~S~4~ 66.36; H, 6.54; N, 3.87.

1-(Benzo\[*d*\] [@pone.0111782-World1], [@pone.0111782-Interim1]dioxin-5-ylmethyl)-6′,7′-dihydrospiro\[piperidine- 4,4′-thieno \[3,2-*c*\]pyran\] 11 {#s4h}
----------------------------------------------------------------------------------------------------------------------------------------------------

Prepared according to general procedure 1. Following purification by flash chromatography (2∶100∶0.2, CH~3~OH∶CH~2~Cl~2~∶NH~4~OH), *the title compound* was obtained as a colourless oil that solidified to a colourless solid when taken to 4°C (37 mg, 44%); mp 81--84°C; ν~max~ (film)/cm^−1^ 2923, 2813, 1501, 1487, 1440, 1242, 1074, 1036, 934, 853, 648; δ~H~ (500 MHz; CDCl~3~) 7.06 (d, *J = *5.2 Hz, 1 *H*), 6.89 (d~app~, *J = *1.0 Hz, 1 *H*), 6.81 (d, *J* = 5.2 Hz, 1 *H*), 6.78 (dd, *J = *8.0, 1.0 Hz, 1 *H*), 6.75 (d~app~, *J = *8.0 Hz, 1 *H*), 3.92 (t~app~, *J = *5.4 Hz, 2 *H*), 3.47 (s, 2 *H*), 2.82 (t~app~, *J = *5.4 Hz, 2 *H*), 2.72--2.70 (m, 2 *H*), 2.40--2.35 (m, 2 *H*), 2.00--1.94 (m, 2 *H*), 1.86--1.83 (m, 2 *H*) ([Figure S17](#pone.0111782.s017){ref-type="supplementary-material"}); δ~C~ (126 MHz; CDCl~3~) 147.7, 146.7, 141.3, 132.73, 132.56, 124.5, 122.48, 122.33, 109.8, 108.0, 101.0, 73.4, 63.3, 59.1, 49.1, 36.3, 26.0 ([Figure S18](#pone.0111782.s018){ref-type="supplementary-material"}); HRMS (ESI) 344.13146 (\[M+H\]^+^), calcd. for C~19~H~22~NO~3~S^+^ 344.13149; Anal. Calcd. for C~19~H~21~NO~3~S: C, 66.45; H, 6.16; N, 4.08. Found: C, 66.59; H, 6.26; N, 3.98.

4-((6′,7′-Dihydrospiro\[piperidine-4,4′-thieno\[3,2-*c*\]pyran\]-1-yl) (2-methoxyphenol) 12 {#s4i}
-------------------------------------------------------------------------------------------

Prepared according to general procedure 1. Following purification by flash chromatography (2∶100∶0.1, CH~3~OH∶CH~2~Cl~2~∶NH~4~OH), *the title compound* was obtained as a colourless solid (41 mg, 44%); mp 170--172°C; ν~max~ (film)/cm^−1^ 2927, 1517, 1277, 1265, 1071, 800, 732; δ~H~ (500 MHz; CDCl~3~) 7.04 (d, *J = *5.2 Hz, 1 *H*), 6.90 (s~app~, 1 *H*), 6.83--6.77 (m, 2+1 *H*), 3.92 (t~app~, *J = *5.4 Hz, 2 *H*), 3.83 (s, 3 *H*), 3.50 (s, 2 *H*), 2.82 (t~app~, *J = *5.4 Hz, 2 *H*), 2.76--2.74 (m, 2 *H*), 2.41--2.36 (m, 2 *H*), 2.83--1.83 (m, 2 *H*), 2.02--1.96 (m, 2 *H*) ([Figure S19](#pone.0111782.s019){ref-type="supplementary-material"}); δ~C~ (126 MHz; CDCl~3~) 146.7, 144.9, 141.1, 132.6, 129.9, 124.4, 122.38, 122.19, 114.2, 112.0, 73.3, 63.3, 59.0, 55.8, 49.0, 42.0, 35.9, 27.0, 25.9, 25.0 ([Figure S20](#pone.0111782.s020){ref-type="supplementary-material"}); **^1^**H --^13^C HSQC ([Figure S21](#pone.0111782.s021){ref-type="supplementary-material"}) spectrum also supplied; HRMS (ESI) 346.14711 (\[M+H\]^+^), calcd. for C~19~H~24~NO~3~S^+^ 346.14714; Anal. Calcd. for C~19~H~23~NO~3~S: C, 66.06; H, 6.71; N, 4.05. Found: C, 65.88; H, 6.91; N, 3.87.

1-(4-Chlorobenzyl)-6′,7′-dihydrospiro\[piperidine-4,4′-thieno\[3,2-*c*\]pyran\] 13 {#s4j}
----------------------------------------------------------------------------------

Prepared according to general procedure 1. Following purification by flash chromatography (3∶100∶0.3, CH~3~OH∶CHCl~3~∶NH~4~OH), *the title compound* was obtained as a colourless oil that solidified when taken to 4°C (79 mg, 64%); mp 106--109°C; ν~max~ (film)/cm^−1^ 2923, 2816, 1489, 1076, 1016, 854, 646; δ~H~ (500 MHz; CDCl~3~) 7.29 (s~app~, 4 *H*), 7.07 (d, *J = *5.2 Hz, 1 *H*), 6.81 (d, *J = *5.2 Hz, 1 *H*), 3.92 (t~app~, *J = *5.4 Hz, 2 *H*), 3.52 (s, 2 *H*), 2.82 (t~app~, *J = *5.4 Hz, 2 *H*), 2.70--2.67 (m, 2 *H*), 2.42--2.36 (m, 2 *H*), 1.99--1.93 (m, 2 *H*), 1.86--1.83 (m, 2 *H*) ([Figure S22](#pone.0111782.s022){ref-type="supplementary-material"}); δ~C~ (126 MHz; CDCl~3~) 141.2, 137.3, 132.8, 130.6, 128.5, 124.5, 122.4, 59.1, 49.2, 36.3, 26.0 ([Figure S23](#pone.0111782.s023){ref-type="supplementary-material"}); HRMS (ESI) 334.10268 (\[M+H\]^+^), calcd. for C~18~H~21~ClNOS^+^ 334.10269; Anal. Calcd. for C~18~H~20~ClNOS: C, 64.75; H, 6.04; N, 4.20. Found: C, 64.56; H, 6.08; N, 4.16.

1-((1-(4-Fluorophenyl)-2,5-dimethyl-1*H*-pyrrol-3-yl)methyl)-6′,7′- dihydrospiro\[piperidine-4,4′-thieno\[3,2-*c*\]pyran\] hydrochloride 14 {#s4k}
-------------------------------------------------------------------------------------------------------------------------------------------

Prepared according to general procedure 1. Following purification by flash chromatography (2∶100∶0.2, CH~3~OH∶CHCl~3~∶NH~4~OH), *the title compound* was obtained as a brown solid (23 mg, 22%); ν~max~ (film)/cm^−1^ 2922, 1511, 1224, 1075, 852; δ~H~ (500 MHz; CDCl~3~) 7.18--7.14 (m, 3 *H*), 6.88 (s, 1 *H*), 6.02 (s, 1 *H*), 3.93 (t~app~, *J = *5.4 Hz, 2 *H*), 3.57 (brs, 2 *H*), 2.97 (brs, 1 H), 2.83 (t~app~, *J = *5.3 Hz, 2 H), 2.54 (s, 2 H), 2.23 (s, 1 H), 1.99 (s, 4 H), 1.91--1.88 (m, 3 H), 1.68 (s, 3 H) ([Figure S24](#pone.0111782.s024){ref-type="supplementary-material"}); δ~C~ (126 MHz; CDCl~3~) 163.0, 161.0, 140.6, 135.0, 135.0, 132.7, 130.1, 130.1, 124.7, 122.6, 116.3, 116.1, 108.6, 72.9, 59.4, 54.4, 48.5, 35.3, 29.8, 26.0, 12.9, 11.1 ([Figure S25](#pone.0111782.s025){ref-type="supplementary-material"}); δ~F~ (471 MHz; CDCl~3~) *-*113.8; HRMS (ESI) 411.19012 (\[M−Cl\]^+^), calcd. for C~24~H~28~FN~2~OS 411.19009; Anal. Calcd. for C~24~H~28~ClFN~2~OS: C, 64.49; H, 6.31; N, 6.27. Found: C, 64.05; H, 6.14; N, 5.95.

1-Cyclohexyl-6′,7′-dihydrospiro\[piperidine-4,4′-thieno\[3,2-*c*\]pyran\] 15 {#s4l}
----------------------------------------------------------------------------

Prepared according to general procedure 1. Following purification by flash chromatography (0.8∶100∶0.08, CH~3~OH∶CHCl~3~∶NH~4~OH) *the title compound* was obtained as a colourless solid (67 mg, 84%); mp 170--172°C; ν~max~ (film)/cm^−1^ 2925, 2854, 1076, 647; δ~H~ (500 MHz; CDCl~3~) 7.05 (d, *J = *5.2 Hz, 1 *H*), 6.84 (d, *J = *5.2 Hz, 1 *H*), 3.92 (t, *J = *5.4 Hz, 2 *H*), 2.82 (t, *J = *5.4 Hz, 2 *H*), 2.78--2.76 (m, 2 *H*), 2.65 (t, *J = *11.6 Hz, 2 *H*), 2.38--2.34 (m, 1 *H*), 2.04--1.81 (m, 8 *H*), 1.66--1.62 (m, 1 *H*), 1.32--1.21 (m, 4 *H*), 1.15--1.08 (m, 1 *H*) ([Figure S26](#pone.0111782.s026){ref-type="supplementary-material"}); δ~C~ (126 MHz; CDCl~3~) 141.2, 132.7, 124.7, 122.3, 73.6, 64.3, 59.1, 44.8, 36.5, 29.0, 26.5, 26.2, 26.0 ([Figure S27](#pone.0111782.s027){ref-type="supplementary-material"}); HRMS (ESI) 292.17301 (\[M+H\]^+^), calcd. for C~17~H~26~NOS^+^ 292.17296; Anal. Calcd. for C~17~H~25~NOS: C, 70.06; H, 8.65; N, 4.81. Found: C, 69.51; H, 8.67; N, 4.70. Discrepancy in CHN analysis noted, but data consistent with 5M + H~2~O i.e. calcd. for C~85~H~127~N~5~O~6~S~5~: C, 69.20; H, 8.68; N, 4.75.

6′,7′-Dihydrospiro\[piperidine-4,4′-thieno\[3,2-c\]pyran\]-1-yl(phenyl) methanone 16 {#s4m}
------------------------------------------------------------------------------------

Prepared according to general procedure 2. Following purification by flash chromatography (1∶100∶0.1, CH~3~OH∶CHCl~3~∶NH~4~OH), *the title compound* was obtained as a colourless solid (60 mg, 66%); mp 170--172°C; ν~max~ (film)/cm^−1^ 2951, 1432, 1050, 709; δ~H~ (500 MHz; CDCl~3~) 7.45--7.40 (m, 5 *H*), 7.10 (d, *J = *5.2 Hz, 1 *H*), 6.76 (d, *J = *5.2 Hz, 1 *H*), 4.67--4.64 (m, 1 *H*), 3.97--3.94 (m, 2 *H*), 3.65--3.60 (m, 1 H), 3.50--3.45 (m, 1 *H*), 3.22--3.16 (m, 1 *H*), 2.85 (t, *J = *5.4 Hz, 2 *H*), 2.01--1.75 (m, 4 *H*) ([Figure S28](#pone.0111782.s028){ref-type="supplementary-material"}); δ~C~ (126 MHz; CDCl~3~; 300 K) 170.5, 140.1, 136.4, 133.0, 129.7, 128.6, 127.1, 124.1, 122.9, 73.5, 59.5, 25.9 ([Figure S29](#pone.0111782.s029){ref-type="supplementary-material"}); δ~C~ (126 MHz; CDCl~3~; 270 K) 170.5, 139.9, 136.0, 133.0, 129.7, 128.6, 127.0, 124.1, 122.9, 73.4, 59.5, 43.7, 38.1, 36.7, 35.5, 25.8; HRMS (ESI) 336.10287 (\[M+Na\]^+^), calcd. for C~18~H~19~NO~2~SNa^+^ 336.10287; Anal. Calcd. for C~18~H~19~NO~2~S: C, 68.98; H, 6.11; N, 4.47. Found: C, 68.03; H, 6.05; N, 4.44. Discrepancy in CHN analysis noted, but data consistent with 4M + H~2~O i.e. calcd. for C~72~H~78~N~4~O~9~S~4~: C, 68.00; H, 6.18; N, 4.41. ^13^C{^1^H} signals are missing or obscured due to rotamers around the amide bond. The signals were visualised using **^1^**H --^13^C HSQC spectroscopy ([Figure S30](#pone.0111782.s030){ref-type="supplementary-material"}) and completely resolved at 270 K ([Figure S40](#pone.0111782.s040){ref-type="supplementary-material"}). Variable temperature NMR data for this compound may be found in [Dataset S1](#pone.0111782.s043){ref-type="supplementary-material"}.

(4-Bromophenyl)(6′,7′-dihydrospiro\[piperidine-4,4′-thieno\[3,2-c\]pyran\]-1-yl) methanone 17 {#s4n}
---------------------------------------------------------------------------------------------

Prepared according to general procedure 2. Following purification by flash chromatography (1∶100∶0.1, CH~3~OH∶CHCl~3~∶NH~4~OH), *the title compound* was obtained as a colourless solid (60 mg, 66%); mp 170--172°C; ν~max~ (film)/cm^−1^ 2923, 1628, 1433, 1072; δ~H~ (500 MHz; CDCl~3~) 7.56--7.52 (m, 2 *H*), 7.39--7.30 (m, 2 *H*), 7.10 (d, *J* = 5.2 Hz, 1 *H*), 6.74 (d, *J* = 5.2 Hz, 1 *H*), 4.65--4.58 (m, 1 *H*), 3.95--3.92 (m, 2 *H*), 3.62--3.44 (m, 2 *H*), 3.23--3.15 (m, 1 *H*), 2.85 (t~app~, *J* = 5.4 Hz, 2 *H*), 2.02--1.83 (m, 2 *H*), 1.83--1.72 (m, 2 *H*) ([Figure S31](#pone.0111782.s031){ref-type="supplementary-material"}); δ~C~ (126 MHz; CDCl~3~) 169.5, 139.9, 135.1, 133.1, 131.8, 128.8, 124.00, 123.97, 122.9, 73.4, 59.5, 25.9 ([Figure S32](#pone.0111782.s032){ref-type="supplementary-material"}); **^1^**H --^13^C HSQC ([Figure S33](#pone.0111782.s033){ref-type="supplementary-material"}) and ^1^H --^13^C{^1^H} HMBC ([Figure S34](#pone.0111782.s034){ref-type="supplementary-material"}) spectra also supplied; HRMS (ESI) 416.01134 (\[M+Na\]^+^), calcd. for C~18~H~18~ ^81^BrNOSNa^+^ 416.01134; Anal. Calcd. for C~18~H~18~BrNO~2~S: C, 55.11; H, 4.62; N, 3.57. Found: C, 55.88; H, 4.89; N, 3.45. ^13^C{^1^H} signals are missing or obscured due to rotamers around the amide bond. Discrepancy in CHN analysis noted; data match sample containing \<10% des-brominated compound, but this was not observed in the ^1^H NMR spectrum for this sample.

(2-Bromophenyl)(6′,7′-dihydrospiro\[piperidine-4,4′-thieno\[3,2-c\]pyran\]-1-yl) methanone 18 {#s4o}
---------------------------------------------------------------------------------------------

Prepared according to general procedure 2. Following purification by flash chromatography (1∶100∶0.1, CH~3~OH∶CH~2~Cl~2~∶NH~4~OH), *the title compound* was obtained as a colourless solid (81 mg, 73%); mp 48--52°C; ν~max~ (film)/cm^−1^ 2932, 1634, 1436, 1073, 768; δ*~H~* (500 MHz; CDCl~3~) 7.60--7.54 (m, 1 *H*), 7.38--7.31 (m, 2 *H*), 7.24 (dd, *J = *13.3, 6.7 Hz, 2 *H*), 7.08 (dd, *J* = 4.8, 2.5 Hz, 1 *H*), 6.72 (d, *J* = 5.2 Hz, 1 *H*), 4.73--4.66 (m, 1 *H*), 3.93 (tq, *J* = 10.0, 4.9 Hz, 2 *H*), 3.55 (td, *J = *12.9, 3.2 Hz,), 3.42--3.34 (m, 1 *H*), 3.28--3.12 (m, 2 *H*), 2.83 (t, *J = *4.9 Hz, 2 *H*), 2.10 (td, *J* = 13.5, 5.0 Hz, 1 *H*), 1.99 (dd, *J* = 9.8, 3.6 Hz, 1 *H*), 1.94--1.90 (m, 1 *H*), 1.81--1.69 (m, 2 *H*), 1.26 (t, *J = *7.2 Hz, 1 *H*), 1.05 (t, *J = *7.1 Hz, \<1 *H*) ([Figure S35](#pone.0111782.s035){ref-type="supplementary-material"}); δ~C~ (126 MHz; CDCl~3~) 167.8, 167.6, 140.0, 139.9, 138.9, 138.5, 138.4, 133.4, 132.9, 132.8, 132.8, 130.3, 130.2, 130.0, 127.8, 127.7, 127.7, 127.6, 127.6, 127.5, 124.1, 123.9, 122.8, 122.8, 119.4, 119.2, 73.4, 73.3, 59.5, 43.5, 42.8, 42.5, 39.0, 37.7, 37.5, 36.6, 36.3, 35.6, 35.5, 31.0, 25.8, 14.0, 12.6 ([Figure S36](#pone.0111782.s036){ref-type="supplementary-material"}); **^1^**H --^13^C HSQC ([Figure S37](#pone.0111782.s037){ref-type="supplementary-material"}) and ^1^H --^13^C{^1^H} HMBC ([Figure S38](#pone.0111782.s038){ref-type="supplementary-material"}) spectra also supplied; HRMS (ESI) 414.01338 (\[M+Na\]^+^), calcd. for C~18~H~18~BrNO~2~SNa^+^ 414.01338; Anal. Calcd. for C~18~H~18~BrNO~2~S: C, 55.11; H, 4.62; N, 3.57. Found: C, 55.36; H, 4.36; N, 3.59. The additional ^13^C{^1^H} and ^1^H signals are due to rotamers around the amide bond.

Resazurin assay of growth inhibition {#s4p}
------------------------------------

Compounds were tested for activity at either single concentration (100 µM) or serially diluted in 10 µL of purified H~2~O in triplicate in 96 well microtiter plates. *M. tuberculosis* H37Rv was grown in complete Middlebrook 7H9 media (Bacto, Australia) containing albumin, dextrose and catalase (ADC), 20% Tween 80 and 50% glycerol (Sigma-Aldrich, Australia). A bacterial suspension (90 µL) at OD~600nm~ of 0.001 was added to the wells and incubated for 7 days. Resazurin (10 µL; 0.05%(w/v); Sigma-Aldrich, Australia) was then added, incubated for 24 h at 37°C, and fluorescence measured at 590 nm using a FLUOstar Omega microplate reader (BMG Labtech, Germany). After subtraction of background fluorescence from all wells, the percentage mycobacterial survival was determined by comparing the fluorescence of wells containing compounds compared to control wells not treated with compound.

Compound intracellular efficacy and toxicity {#s4q}
--------------------------------------------

THP1 cells (TIB-202R), a human monocyte cell line (American Type Culture Collection, USA), were grown in complete Dulbecco\'s Modified Eagle Media (DMEM; LifeTechnologies, Australia) including 10% fetal bovine serum (FBS), 200 µM L-glutamine (LifeTechnologies, Australia), and 1 mM HEPES buffer solution (LifeTechnologies, Australia). Cells (1×10^5^) in media containing 50 ng/mL phorbol 12-myristate 13-acetate (PMA) were added to 96-well plates and were then incubated for 48 h at 37°C to allow adherence and differentiation. Compounds (1.56--200 µM) were added to the wells and incubated for 4 days at 37°C. Then 0.05%(w/v) resazurin (4 h) was added and the fluorescence measured. Cell viability was calculated as percentage fluorescence in comparison to untreated cells.
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(EPS)

###### 

Click here for additional data file.

###### 

^1^H NMR (500 MHz, CDCl~3~) spectrum of 4-((6′,7′-dihydrospiro\[piperidine-4,4′-thieno\[3,2-*c*\]pyran\]-1-yl) (2-methoxyphenol) **12**.

(EPS)

###### 

Click here for additional data file.

###### 

**^13^**C{^1^H} NMR (126 MHz, CDCl~3~) spectrum of 4-((6′,7′-dihydrospiro\[piperidine-4,4′-thieno\[3,2-*c*\]pyran\]-1-yl) (2-methoxyphenol) **12**.

(EPS)

###### 

Click here for additional data file.

###### 

**^1^**H --^13^C HSQC (500 MHz, CDCl~3~) spectrum of 4-((6′,7′-dihydrospiro\[piperidine-4,4′-thieno\[3,2-*c*\]pyran\]-1-yl) (2-methoxyphenol) **12**.

(EPS)

###### 

Click here for additional data file.

###### 

^1^H NMR (500 MHz, CDCl~3~) spectrum of 1-(4-chlorobenzyl)-6′,7′-dihydrospiro\[piperidine-4,4′-thieno\[3,2-*c*\]pyran\] **13**.

(EPS)

###### 

Click here for additional data file.

###### 

^13^C{^1^H} NMR (126 MHz, CDCl~3~) spectrum of 1-(4-chlorobenzyl)-6′,7′-dihydrospiro\[piperidine-4,4′-thieno\[3,2-*c*\]pyran\] **13**.

(EPS)

###### 

Click here for additional data file.

###### 

^1^H NMR (500 MHz, CDCl~3~) spectrum of 1-((1-(4-fluorophenyl)-2,5-dimethyl-1*H*-pyrrol-3-yl)methyl)-6′,7′- dihydrospiro\[piperidine-4,4′-thieno\[3,2-*c*\]pyran\] hydrochloride **14**.

(EPS)

###### 

Click here for additional data file.

###### 

^13^C{^1^H} NMR (126 MHz, CDCl~3~) spectrum of 1-((1-(4-fluorophenyl)-2,5-dimethyl-1*H*-pyrrol-3-yl)methyl)-6′,7′- dihydrospiro\[piperidine-4,4′-thieno\[3,2-*c*\]pyran\] hydrochloride **14**.

(PDF)

###### 

Click here for additional data file.

###### 

^1^H NMR (500 MHz, CDCl~3~) spectrum of 1-cyclohexyl-6′,7′-dihydrospiro\[piperidine-4,4′-thieno\[3,2-*c*\]pyran\] **15**.

(EPS)

###### 

Click here for additional data file.

###### 

^13^C{^1^H} NMR (126 MHz, CDCl~3~) spectrum of 1-cyclohexyl-6′,7′-dihydrospiro\[piperidine-4,4′-thieno\[3,2-*c*\]pyran\] **15**.

(EPS)

###### 

Click here for additional data file.

###### 

^1^H NMR (500 MHz, CDCl~3~) spectrum of 6′,7′-dihydrospiro\[piperidine-4,4′-thieno\[3,2-c\]pyran\]-1-yl(phenyl) methanone **16**.

(EPS)

###### 

Click here for additional data file.

###### 

^13^C{^1^H} NMR (126 MHz, CDCl~3~) spectrum of 6′,7′-dihydrospiro\[piperidine-4,4′-thieno\[3,2-c\]pyran\]-1-yl(phenyl) methanone **16**.

(EPS)

###### 

Click here for additional data file.

###### 

**^1^**H --^13^C HSQC (500 MHz, CDCl~3~) spectrum of 6′,7′-dihydrospiro\[piperidine-4,4′-thieno\[3,2-c\]pyran\]-1-yl(phenyl) methanone **16**.

(EPS)

###### 

Click here for additional data file.

###### 

^1^H NMR (500 MHz, CDCl~3~) spectrum of (4-bromophenyl)(6′,7′-dihydrospiro\[piperidine-4,4′-thieno\[3,2-c\]pyran\]-1-yl) methanone **17**.

(EPS)

###### 

Click here for additional data file.

###### 

^13^C{^1^H} NMR (126 MHz, CDCl~3~) spectrum of (4-bromophenyl)(6′,7′-dihydrospiro\[piperidine-4,4′-thieno\[3,2-c\]pyran\]-1-yl) methanone **17**.

(EPS)

###### 

Click here for additional data file.

###### 

**^1^**H --^13^C HSQC (500 MHz, CDCl~3~) spectrum of (4-bromophenyl)(6′,7′-dihydrospiro\[piperidine-4,4′-thieno\[3,2-c\]pyran\]-1-yl) methanone **17**.

(EPS)

###### 

Click here for additional data file.

###### 

^1^H --^13^C{^1^H} HMBC (500 MHz, CDCl~3~) spectrum of (4-bromophenyl)(6′,7′-dihydrospiro\[piperidine-4,4′-thieno\[3,2-c\]pyran\]-1-yl) methanone **17**.

(EPS)

###### 

Click here for additional data file.

###### 

^1^H NMR (500 MHz, CDCl~3~) spectrum of (2-bromophenyl)(6′,7′-dihydrospiro\[piperidine-4,4′-thieno\[3,2-c\]pyran\]-1-yl) methanone **18**.

(EPS)

###### 

Click here for additional data file.

###### 

^13^C{^1^H} NMR (126 MHz, CDCl~3~) spectrum of (2-bromophenyl)(6′,7′-dihydrospiro\[piperidine-4,4′-thieno\[3,2-c\]pyran\]-1-yl) methanone **18**.

(EPS)

###### 

Click here for additional data file.

###### 

**^1^**H --^13^C HSQC (500 MHz, CDCl~3~) spectrum of (2-bromophenyl)(6′,7′-dihydrospiro\[piperidine-4,4′-thieno\[3,2-c\]pyran\]-1-yl) methanone **18**.

(EPS)

###### 

Click here for additional data file.

###### 

^1^H --^13^C{^1^H} HMBC (500 MHz, CDCl~3~) spectrum of (2-bromophenyl)(6′,7′-dihydrospiro\[piperidine-4,4′-thieno\[3,2-c\]pyran\]-1-yl) methanone **18**.

(EPS)

###### 

Click here for additional data file.

###### 

^1^H NMR (CDCl~3~) spectra (4.5--2.5 ppm) of 6′,7′-dihydrospiro\[piperidine-4,4′-thieno\[3,2-c\]pyran\]-1-yl(phenyl) methanone **16** at variable temperature and magnetic field strength.

(EPS)

###### 

Click here for additional data file.

###### 

Overlay of the ^13^C{^1^H} NMR (126 MHz, CDCl~3~) spectra of 6′,7′-dihydrospiro\[piperidine-4,4′-thieno\[3,2-c\]pyran\]-1-yl(phenyl) methanone **16** at 300 K and 270 K.

(EPS)

###### 

Click here for additional data file.

###### 

**General synthetic and chemical analysis methods.**

(RTF)

###### 

Click here for additional data file.

###### 

**Summary of the experimental the experimental data.**

(XLSX)

###### 

Click here for additional data file.

###### 

Variable Temperature NMR Data for Compound **16**.

(ZIP)

###### 

Click here for additional data file.

Synthesis of the novel arylpyrrole **14** was possible through the kind provision of the relevant aldehyde by Dr. Alice Williamson (The University of Sydney). We are grateful to technical assistance from Dr. Ian Luck (NMR spectroscopy), Mr. John Twyman (electronic lab notebook) and Dr. Nick Proschogo (mass spectrometry); elemental analyses were performed at The Campbell Microanalytical Laboratory, University of Otago. The electronic lab notebook used was the open source Labtrove software developed at the University of Southampton ([www.labtrove.org](http://www.labtrove.org)); we thank the Labtrove team for help in creating the browseable snapshot.

[^1]: **Competing Interests:**Matthew Todd is a PLOS ONE Editorial Board Member (as an Associate Editor). This does not alter the authors\' adherence to PLOS ONE Editorial policies and criteria.

[^2]: Conceived and designed the experiments: KAB JAT MHT. Performed the experiments: KAB DHQ. Analyzed the data: KAB DHQ JAT MHT. Contributed reagents/materials/analysis tools: KAB DHQ. Wrote the paper: KAB JAT MHT.
